読み込み中
NASDAQHealthcareDrug Manufacturers - General
最新データ
$2.92
−$0.04 · -1.35%
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
前日終値
$2.92
−$0.04 · -1.35%
日中の時刻はETです。市場データは遅延する場合があります。
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
日中レンジ
現在 $2.92
52週レンジ
現在 $2.92
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
38
割高
センチメント
55
まちまち
リスク
75
高リスク
モメンタム
51
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
日中レンジ
現在 $2.92
52週レンジ
現在 $2.92
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3025.3万 USD | 5659万 USD | 4674.3万 USD | 3803.4万 USD | 3131.7万 USD |
| 売上原価 | 1522.2万 USD | 1668.9万 USD | 1568.1万 USD | 1079.7万 USD | 363.4万 USD |
| 粗利益 | 1503.1万 USD | 3990.1万 USD | 3106.2万 USD | 2723.7万 USD | 2768.3万 USD |
| 研究開発 | 2071万 USD | 964.1万 USD | 1274.6万 USD | 905.4万 USD | 920.1万 USD |
| 販売・一般管理 | 2.67億 USD | 1.19億 USD | 1.2億 USD | 6489.5万 USD | 5058.2万 USD |
| 営業費用 | 2.87億 USD | 1.23億 USD | 1.36億 USD | 7787.1万 USD | 6352.1万 USD |
| 支払利息 | 1145.9万 USD | 196.3万 USD | 106.8万 USD | 960.4万 USD | 1176.4万 USD |
| 減価償却費と償却費 | 462.3万 USD | 404.6万 USD | 414.6万 USD | 396.1万 USD | 377.9万 USD |
| 営業利益 | −2.72億 USD | −8339.6万 USD | −1.05億 USD | −5063.4万 USD | −3583.8万 USD |
| 純利益 | −3.59億 USD | −7280.7万 USD | −1.14億 USD | −2336.4万 USD | −8842.4万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年4月15日 | 1:35 | — | — |
発効済み 2025年4月15日
1:35
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI119.52万0.00%2.3兆 USD0.03%$381.94—
Vanguard Extended Market ETFVXF41.89万0.00%954億 USD0.05%$235—
iShares Micro-Cap ETFIWC7.08万0.01%13.17億 USD0.60%$183—
Avantis Total Equity Markets ETF 1AVTM236.8—7.94億 USD0.23%$55.6085—
Dimensional - US Core Equity Market ETFDFAU195.360.00%——$53.43—Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAvantis Total Equity Markets ETF 1AVTMDimensional - US Core Equity Market ETFDFAUAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
